GlaxoSmithKline (GSK) plans to present updates about emerging studies from the company’s comprehensive respiratory portfolio of investigational programs, approved medicines and scientific collaborations.
A recent study suggests that a commonly used diabetes drug could inhibit the weight gain that children and teens with autism typically experience when they take two medicines that are designed to decrease their agitation.
A team of researchers at the National Center for Advancing Translational Sciences (NCATS), a branch of the National Institutes of Health (NIH), recently discovered compounds that may be useful for stopping the Zika virus.
The American Heart Association (AHA) 'Rapid Access Journal Report' recently stated that researchers have discovered a connection between late-onset asthma and an increased risk of heart disease and stroke.
The National Institutes of Health’s National Institute on Minority Health and Health Disparities (NIMHD) recently established the Transdisciplinary Collaborative Centers (TCC) for Health Disparities Research on Chronic Disease Prevention.
The American Cancer Society recently published 'Breast Cancer Clear & Simple, Second Edition: All Your Questions Answered' to give newly diagnosed breast cancer patients more hope and information about their health.
Leaders from ViiV Healthcare have launched a phase III program to find more supportive evidence for its dolutegravir (Tivicay) and lamivudine (Epivir) treatments, which are designed for adults with HIV-1 infections.
The National Institute of Allergy and Infectious Disease (NIAID) recently reported that people with Ebola virus infections are 20 percent more likely to overcome the infection and survive if they also had co-infections of Plasmodium parasites, which cause malaria.
The Tuberous Sclerosis Alliance (TS Alliance) recently announced that it has created the Engles Collaborative Research Fund, which will give $1.5 million to research for tuberous sclerosis complex (TSC) solutions.
Scientists with the National Institutes of Allergy and Infectious Diseases (NIAD), a branch of the National Institutes of Health (NIH), recently began a clinical trial for a vaccine candidate that is designed to stop Zika virus infections.